ACADIA PHARMACEUTICALS INC (ACAD)

Acadia Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 14, 2025

Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Acadia Pharmaceuticals Announces Closing of Sale of Rare Pediatric Disease Priority Review Voucher for $150 Million

Acadia Pharmaceuticals Appoints Thomas Garner Chief Commercial Officer

Bullish Two Hundred Day Moving Average Cross - ACAD

Acadia Pharmaceuticals Announces Exclusive License Agreement with Saniona for SAN711

Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences

Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Acadia Pharmaceuticals Breaks Above 200-Day Moving Average - Bullish for ACAD

Acadia Pharmaceuticals Reports Third Quarter 2024 Financial Results and Operating Overview

Acadia Pharmaceuticals Enters Into an Agreement to Sell its Rare Pediatric Disease Priority Review Voucher for $150 Million

Acadia Pharmaceuticals to Announce Third Quarter Financial Results on November 6, 2024

Acadia Pharmaceuticals Announces Health Canada Approval of DAYBUE™ (trofinetide) for the Treatment of Rett Syndrome

Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Notable Tuesday Option Activity: AGIO, AAOI, ACAD

Catherine Owen Adams Succeeds Steve Davis as CEO of Acadia Pharmaceuticals

Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences

Ryan Reynolds Announces More to Parkinson’s® Campaign

Acadia Pharmaceuticals to Participate in the Canaccord Genuity 44th Annual Growth Conference

Biotech Stocks: Why Acadia Pharma And Others Are Feeling 'Growing Pains'

Acadia led a biotech selloff on Wednesday as Daybue sales missed expectations.

Acadia Pharmaceuticals Reports Second Quarter 2024 Financial Results and Operating Overview

Acadia Pharmaceuticals to Announce Second Quarter Financial Results on August 6, 2024

Clinical Data from Open-Label Extension LILAC-1™ and LILAC-2™ Studies Evaluating Long-Term Safety and Efficacy of DAYBUE™ (trofinetide) in Patients with Rett Syndrome Published in Med

Acadia Pharmaceuticals Presents DAYBUE™ (trofinetide) Real-World Evidence and Additional Data in Rett Syndrome at the 2024 International Rett Syndrome Foundation (IRSF) Annual Scientific Meeting

3 Sorry Pharma Stocks to Sell in May While You Still Can

Discover three pharma stocks to sell in May while you still can. Avoid these companies facing significant setbacks.

Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

ACAD July 19th Options Begin Trading

Acadia Pharmaceuticals Announces Launch of Magnolia's Guide to Adventuring: A Groundbreaking Documentary Series Aiming to Raise Disease Awareness and Redefine Perceptions of Rett Syndrome

Shhh! 3 Secret Penny Stocks Flying Below Wall Street’s Radar

Under-the-radar penny stocks can be some of the most rewarding investments on the market. Here are three to consider.